FOLH1 and neoplasm: While an anti-PSMA antibody β-emitter was associated with hematologic toxicity 10, small molecule β-emitters targeting PSMA (e.g.177Lu-PSMA617) have shown anti-tumor efficacy with minimal hematologic toxicity 9,12.